Clinical Trial Update: Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies [EARLY_Phase 1]

View source ↗

Summary

Early phase1 trial evaluating vandetanib-eluting radiopaque embolic beads for resectable liver malignancies has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Hepatocellular Carcinoma

Drugs mentioned

• Vandetanib (vandetanib)
• vandetanib-eluting radiopaque embolic beads (vandetanib-eluting radiopaque embolic beads)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Carcinoma, Hepatocellular, Metastatic Colorectal Cancer | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2021-02-03